Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - suguhormoonid ja immunoglobuliinid, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Eesti - eesti - Ravimiamet

roche pharma ag - kasirivimab+imdevimab - infusioonilahuse kontsentraat - 120mg+120mg 1ml 20ml 2tk

Eesti - eesti - Ravimiamet

genentech inc. - kasirivimab+imdevimab - infusioonilahuse kontsentraat - 120mg+120mg 1ml 20ml 2tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. vt lõigud 4. 4 ja 5.